Hi Mason, the points you make in this post are the very reason RAC needs to get Bisantrene to market post haste.
Current SoC has been around for over 50 years and is a terrible treatment for an insidious disease; quite simply it poisons the body while treating the cancer, any adjunct drug which can alleviate the damage that is done is needed asap; but herein lies the problem.
Current SoC; ie chemotherapy will eventually be replaced with vastly less toxic immunotherapy treatments and this is happening at an ever increasing rate, there are also vastly improving treatments in the wind for blood cancer.
Yes, these new therapies are a little way off yet but they’re definitely coming so Bisantrene needs to be commercialized before medical science overtakes chemotherapy.
Cardioprotection thread, page-657
-
- There are more pages in this discussion • 249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |